This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

PATH Resources

Our online catalog indexes publications, presentations, and related resources for peers in our field.

20 Resources
20 Resources
20 Resources
    Date
  1. Cryptosporidium is an intestinal protozoan parasite that is a major cause of diarrheal disease among young children in low-resource settings. Beyond diarrheal disease, cryptosporidiosis is associated with other chronic conditions, including growth faltering, environmental enteric dysfunction, and possibly impaired cognitive development. Current therapeutic options are limited, with only one drug, nitazoxanide, approved by the United States Food and Drug Administration. There is only one drug in clinical trials against Cryptosporidium: clofazimine, a repurposed leprosy drug developed more than three decades ago. There are no vaccines for Cryptosporidium approved or in clinical development. This poster summarizes key initiatives to develop new Cryptosporidium drugs, including an overview of PATH's portfolio.
    Published: November 2018
    Type: Resource Page
  2. PATH delivers statement at the 71st World Health Assembly on addressing the global shortage of, and access to, medicines and vaccines.
    Published: May 2018
    Type: Resource Page
  3. The Cryptosporidium parasite is one of the leading causes of diarrheal disease among young children. This report shares highlights from PATH’s 2nd Symposium on Innovative Therapeutics for Cryptosporidium, where experts presented about the state of work in discovery, development, and commercialization of innovative treatments.
    Published: March 2018
    Type: Resource Page
  4. This fact sheet describes PATH’s work to increase access to oxygen therapy for the treatment of life-threatening pneumonia and hypoxemia in newborns and children. Facilitating inclusion of expanded uses of oxygen on the World Health Organization’s Essential Medicines List, as well as the inclusion of oxygen technologies and pulse oximetry in global commodity lists and treatment guidelines, are essential for reducing child mortality.
    Published: December 2017
    Type: Resource Page
  5. Oxygen is listed on the World Health Organization’s Model List of Essential Medicines (EML) and EML for children. This infographic, aimed at advocates and decision-makers, describes the “what,” “where,” “how,” and “how much” behind oxygen programs, and urges countries to align national policies to prioritize oxygen therapy across the entire health system.
    Published: August 2017
    Type: Resource Page
Load more